Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: a post hoc pooled analysis of two clinical studies

BACKGROUND: The use of quality measures attempts to improve safety and health outcomes and to reduce costs. In two Phase III trials in treatment-naive patients with type 2 diabetes, dapagliflozin 5 or 10 mg/d as initial combination therapy with metformin extended-release (XR) significantly reduced g...

Descripción completa

Detalles Bibliográficos
Autores principales: Bell, Kelly F, Katz, Arie, Sheehan, John J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072521/
https://www.ncbi.nlm.nih.gov/pubmed/27790048
http://dx.doi.org/10.2147/RMHP.S108586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072521/
https://www.ncbi.nlm.nih.gov/pubmed/27790048
http://dx.doi.org/10.2147/RMHP.S108586

Ejemplares similares